Clinical trials: Scar Prevention
- Condition Scar Prevention
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Scar Prevention
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery
This study will compare how well EXC 001 works to improve the appearance of scars in subjects undergoing breast scar revision surgery. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
- Trial name
- NCT01037413
- Testing
- EXC 001
- Where
- 5 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cicatrix, Scar Prevention
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
The primary purpose of this study is to evaluate the safety and tolerability of a single intradermal administration of RXI-109 at small surgical incisions in the abdominal skin that will later be removed during an elective…
- Trial name
- NCT01640912
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Scar Prevention
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
- Trial name
- NCT01037985
- Testing
- EXC 001
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertrophic Scar
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
- Trial name
- NCT02246465
- Testing
- RXI-109
- Where
- 6 sites in United States, Honduras
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Hypertrophic Scar
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.
- Trial name
- NCT02030275
- Testing
- RXI-109
- Where
- 5 sites in United States, Honduras
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Scars
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.
- Trial name
- NCT00450775
- Testing
- Dermatix Q
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Innovative Medical
Hypertrophic Scar
Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
- Trial name
- NCT03133130
- Testing
- BMT101
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hugel
Scar Prevention
Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
- Trial name
- NCT01038297
- Testing
- EXC 001
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cicatrix, Scar Prevention
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109
The purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy volunteers.
- Trial name
- NCT01780077
- Testing
- RXI-109
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Keloid
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
- Trial name
- NCT02079168
- Testing
- RXI-109
- Where
- 3 sites in United States, Dominican Republic
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Cicatrix, Scar Prevention
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.
- Trial name
- NCT04707131
- Testing
- LEM-S401
- Where
- South Korea
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Lemonex Inc.